Citations

Clear

367 citation(s) found for "Su, Pan".

Sex Differences in the Impact of Atherosclerotic Cardiovascular Risk Burden on Cognitive Health
Kua, Zaylea , Wang, Xuan , Low, Audrey , Cai, Xueli , Li, Shan, Wang, Mengxing, Wang, Yongjun , Dong, Yanhong , Pan, Yuesong , Wang, Xuan , Low, Audrey , Cai, Xueli , Li, Shan , Wang, Yongjun , Dong, Yanhong , Pan, Yuesong , Zuo, Lijun

Mayo Clinic

Journal of the American Heart Association | August 29, 2025 | Volume: 14 | Issue: 17 | Pages: No page available

10.1161/jaha.125.042741 | PMID 40879031 Get It

Background Sex affects the prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors but whether sex differences exist in the associations between ASCVD risk burden and cognitive function is unclear. Methods This cross‐sectional study included participants from a population‐based cohort study in China that recruited community‐dwelling adults aged 50 to 75 years without baseline cardiovascular disease and stroke. The 10‐year ASCVD risk burden was quantified with 3 multivariate risk prediction equations. Cognitive domains of memory, attention, visuospatial function, executive function, and processing speed were assessed. Multivariable linear regression models were used to examine the interaction terms between sex and ASCVD risk scores on cognition. Results The final analytical sample included 2180 participants. Mean±SD age was 60.14 (6.38) and 52.1% were women. Men showed significantly higher ASCVD risk burden than women at baseline but the effect of ASCVD risk on 2‐year cognition were amplified in women compared with men, for the domains of memory (eg, β=−0.20 [95% CI, –0.26 to −0.13] versus β=−0.11 [95% CI, –0.16 to −0.07]), executive function (eg, β=−0.23 [95% CI, –0.31 to −0.16] versus β=−0.16 [95% CI, –0.21 to −0.10]), and processing speed (eg, β=−0.33 [95% CI, –0.39 to −0.27] versus β=−0.17 [95% CI, –0.21 to −0.13]). Sex‐stratified analyses showed different neuropsychological profiles at moderate ASCVD risk burden levels, suggesting sex‐specific ASCVD‐risk related cognitive phenotypes. Conclusions Sex differences in cognitive health affected by ASCVD risk underscore the importance of sex‐specific cognitive monitoring during ASCVD risk management and better vascular risk control in women to prevent cognitive decline.
Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling
Liang, Wenying , Yang, Zhixia , Hoy, Claire K., Wang, Qiuyu , Ding, Zetao , Pan, Haoyu , Shen, Yiran , Sarosh, Cyrus , Yalavarthi, Srilakshmi , Kapoor, Pooja, Hudgins, Lucas , Vance, Caroline E., Bogle, Rachael , Tambralli, Ajay , Yang, Chengde , Zuo, Yu , Billi, Allison C. , Tsou, Pei‐Suen , Shi, Hui , Liang, Wenying , Ding, Zetao , Shen, Yiran , Sarosh, Cyrus , Yalavarthi, Srilakshmi , Hudgins, Lucas , Wasikowski, Rachael , Figueroa-Parra, Gabriel , Madison, Jacqueline A , Gudjonsson, Johann E , Yang, Chengde , Billi, Allison C , Zuo, Yu , Shi, Yue, Kapoor, Pooja, Figueroa‐Parra, Gabriel , Madison, Jacqueline A. , Tsoi, Lam C. , Duarte‐García, Alí , Knight, Jason S

Mayo Clinic

Circulation | August 29, 2025 | Volume: 152 | Issue: 18 | Pages: 1295-1310

10.1161/circulationaha.125.073552 | PMID 40878676 Get It

BACKGROUND: Whereas antiphospholipid syndrome (APS) is best known for increasing the risk of macrovascular thrombosis, APS vasculopathy is characterized by the abnormal proliferation of endothelial and smooth muscle cells, leading to occlusion of small blood vessels in the skin, kidneys, and heart, among other organs. The underlying mechanisms remain unclear, and targeted treatment options for patients with APS are lacking. METHODS: To identify and analyze APS microvascular endothelial cells (MVECs), skin biopsies of patients with APS complicated by livedo racemosa were characterized using single-cell RNA sequencing. CCN1 (cellular communication network factor 1) and CCN2 were identified in skin and kidney biopsies by immunofluorescence microscopy and in plasma by ELISA. Healthy dermal MVECs were cultured with APS patient–derived serum or immunoglobulin G (IgG), and relevant signaling pathways were characterized using quantitative PCR, immunoblotting, and immunofluorescence microscopy. The proliferation and migration of vascular smooth muscle cells were determined after exposure to conditioned medium from APS IgG–stimulated MVECs. A mouse model of APS IgG–accelerated neointima formation was developed. Anti-CCN2 monoclonal antibodies were tested in vascular smooth muscle cell functional assays and the mouse model. RESULTS: Increased endothelial cell expression of CCN1 and CCN2 was identified by single-cell RNA sequencing and further confirmed in APS skin by microscopy as well as in APS plasma by ELISA. Exposure of healthy MVECs to patient IgG triggered the upregulation of CCN1 and CCN2 via Toll-like receptor 4– and YAP1 (yes-associated protein 1)–mediated signaling. CCN2, originating from APS IgG–stimulated MVECs led to the proliferation and migration of vascular smooth muscle cells, phenotypes that were inhibited by an anti-CCN2 antibody or depletion of EGFR (epidermal growth factor receptor). We further observed increased expression of CCN2, along with evidence of YAP1 nuclear translocation, in kidney vessels of APS nephropathy biopsies. Finally, CCN2 inhibition with an anti-CCN2 monoclonal antibody significantly reduced neointima thickening and cell proliferation in a mouse model of APS IgG–accelerated neointima formation. CONCLUSIONS: This study revealed activation of YAP1-mediated signaling in APS dermal microvessels and demonstrated that the YAP1 target CCN2 plays a role in facilitating pro-proliferative communication between MVECs and vascular smooth muscle cells. These findings offer insights into the cellular and molecular mechanisms underlying APS vasculopathy, providing potential therapeutic targets for patients.
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder
Paner, Gladell P. , Cunha, Isabela W. , Amin, Mahul B. , Aron, Manju , Athanazio, Daniel Abensur , Bambury, Richard , Cheng, Liang, Gopalan, Anuradha , Gulmann, Christian, Harris, Carole A. , Jiménez, Rafael E. , Jinzaki, Masahiro , Lal, Priti , Miyai, Kosuke , Netto, George J. , Pan, Chin-Chen, Rhijn, Bas W. van, Smith, Steven C. , Wobker, Sara E. , Reis, Henning , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular, Cheng, Liang , Cheng, Liang , Al-Ahmadie, Hikmat A , Gaisa, Nadine Therese , López-Beltrán, Antonio , Maclean, Fiona M. , Tsuzuki, Toyonori , Aning, Jonathan J. , Guo, Charles Chuanhai , Iyer, Gopa , Kikuchi, Eiji , Pan, Chin‐Chen , Panebianco, Valeria , Siefker-Radtke, Arlene Odelia , Szarvas, Tibor , Kristiansen, Glen , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular

Mayo Clinic

Advances in Anatomic Pathology | August 4, 2025 | Volume: 33 | Issue: 1 | Pages: 1-16

10.1097/pap.0000000000000510 | PMID 40757456 Get It

The Dublin ISUP Consensus Conference covered the proceedings on the best practice recommendations on nonurachal glandular lesions of the urinary bladder, bladder diverticular cancers, and molecular features of bladder and urachal glandular lesions. The conference proceedings on urachal neoplasms (except for their molecular features) are published elsewhere. The rationale for convening this conference was the lack of structured and consented pathologic recommendations in these rare lesions. Consensus by participants was reached on the following statements: (1) intestinal metaplasia with dysplasia is considered to be a precursor to primary bladder adenocarcinoma; (2) dysplasia arising from cystitis glandularis should be reported in terms of focality (focal or nonfocal) and grade (low or high); (3) the term “adenocarcinoma” should only be used for carcinomas showing pure (nonurothelial) morphology and should not be used interchangeably in urothelial carcinoma with “glandular differentiation” because of the pathobiological differences and management implications; (4) the different histologic subtypes of bladder adenocarcinoma should be specified in the report; (5) immunohistochemistry has an ancillary role in the work up of bladder adenocarcinoma versus gastrointestinal or Müllerian-type adenocarcinomas; (6) lymphovascular invasion should be included as a parameter when reporting bladder adenocarcinoma; (7) representative or targeted sampling will be sufficient for bladder diverticulum resection specimens; and (8) molecular analysis in genomic profiling should be performed only in advanced or metastatic bladder and urachal adenocarcinomas for targetable therapy. This report on glandular (nonurachal) lesions of the bladder from the Dublin ISUP consensus conference will serve as a best practice recommendation and as a guide for future research on these relatively rare lesions.
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
Dhakal, Binod , Akhtar, Othman Salim , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed, Martinez, Mariola Alejandra Vazquez, Wagner, Charlotte B , Davis, James A. , Afrough, Aimaz , Bhutani, Manisha , Freeman, Ciara L. , Mikkilineni, Lekha , Raza, Shahzad , Anderson, Larry D. , Kapoor, Prashant , Hosoya, Hitomi , Gaballa, Mahmoud , Midha, Shonali , Alsina, Melissa , Sborov, Douglas W. , Patel, Krina K. , Lin, Yi , Ferreri, Christopher J. , Kumar, Anupama, Cowan, Andrew J., Sidana, Surbhi , Jensen, Alexandria , Banerjee, Rahul , Friend, Reed , Vazquez-Martinez, Mariola A , Wagner, Charlotte , Davis, James A , Castaneda Puglianini, Omar , Dima, Danai , Bhutani, Manisha , Parrondo, Ricardo D , Freeman, Ciara L , Anderson, Larry D , Hosoya, Hitomi , Chhabra, Saurabh , Grajales-Cruz, Ariel F , Sborov, Douglas W , Patel, Krina , Hansen, Doris K , Costa, Luciano J , Merz, Maximilian , Sidana, Surbhi , Raza, Shahzad , Dhakal, Binod , Fandrei, David , Pan, Darren , Richard, Shambavi , Rees, Matthew J. , Costello, Patrick , Vazquez‐Martinez, Mariola , Pasvolsky, Oren , Puglianini, Omar Castañeda , Reshef, Ran , Dima, Danai , Nadeem, Omar , Chhabra, Saurabh , Grajales‐Cruz, Ariel , Gagelmann, Nico , Hansen, Doris K. , Costa, Luciano J. , Merz, Maximilian

Mayo Clinic

Blood | August 1, 2025 | Volume: 146 | Issue: 17 | Pages: 2063-2072

10.1182/blood.2025029773 | PMID 40749169 Get It

Abstract Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), 2 B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR-T) therapies, have transformed outcomes for relapsed/refractory multiple myeloma; however, the 6 to 8 weeks manufacturing time risks disease progression or death in up to 10% of patients. Talquetamab, a G-protein–coupled receptor, family C, group 5, member D (GPRC5D)–targeting bispecific antibody, represents a promising option. We performed a multi-institutional retrospective analysis across 20 centers (18 United States, 2 Germany) evaluating talquetamab as a bridging therapy prior to cilta-cel or ide-cel. Among 134 patients receiving talquetamab, 119 proceeded to CAR-T (n = 98 cilta-cel, n = 21 ide-cel). Reasons for not proceeding (n = 15) included progression (n = 7), manufacturing failure (n = 6), or patient decision (n = 2). Median age was 65 years and had median 5 prior lines of therapy. Notably, 85% would not have met CARTITUDE-1/KarMMa eligibility criteria. Talquetamab was administered for a median 23 days. Toxicity was manageable: no grade ≥3 cytokine release syndrome (CRS), 2% grade 3 immune effector cell–associated neurotoxicity syndrome (ICANS) and grade 1 to 2 talquetamab unique toxicities (70% oral, 38% skin, and 17% nail; 60% resolved). Talquetamab achieved 71% response rate. After CAR-T, 88% responded (54% complete response), with low-grade toxicities (2 grade ≥3 CRS, 1 grade 3 ICANS, and 5% grade ≥3 infections). Two cases of facial palsy and 1 acute myeloid leukemia occurred. Talquetamab correlated with sustained soluble BCMA decline and peak CAR-T expansion around day 14. Talquetamab bridging appears safe, enabling the majority of difficult-to-treat patients to successfully proceed to BCMA CAR-T therapy.
Karyotypic clonal fraction predicts adverse outcome in TP53 -mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study
Pandiri, M, Stengel, Anna , Shao, Haipeng , Velmurugan, S. , Jacob, Anisha, Symes, Emily , Kaur, Amandeep , Rojek, Alexandra E. , Sojitra, Payal , Wiredja, Danica , Chang, Hong , Patil, Esha, Patel, Jay , Patel, Ami B. , Pan, Zenggang , Findley, Anthony, Badar, Talha , Tariq, Hamza , Sallman, David A. , Bell, Robert , Perry, Anamarija M. , Fitzpatrick, Carrie , Pandiri, Madhavi , Zhou, Qianghua , Venkataraman, Girish , Badar, Talha , Rojek, Alexandra E , Zhang, Jingjing , Wang, Peng , Shao, Haipeng, Jacob, Anisha, Menon, Madhu P , Ghosh, Sharmila , Wool, Geoffrey D. , Arber, Daniel A. , Findley, Anthony, Haferlach, Claudia

Mayo Clinic

Journal of Clinical Pathology | June 26, 2025 | Volume: 78 | Issue: 9 | Pages: 629-635

10.1136/jcp-2024-209954 | PMID 40571403 Get It

We investigated the prognostic impact of blast counts, TP53 allelic state determinants (number of hits, del(17p), variant allele frequency, complex karyotype),and a novel karyotypic clonal cell fraction (≤50% clonal cells vs >50% clonal cells (termed ‘CK50’)) in 495 individuals with TP53- mutated ( TP53 MUT ) myeloid neoplasms. Outcome examined was 24-month survival (OS24). The cohort (median age 71) included 29% (144/495) myelodysplastic syndromes (MDS)/MDS-acute myeloid leukaemia (AML) (1%–19% blasts) and 71% (351/495) AML (≥20% blasts), with 18% (81/460) having low CK50. Overall, 83% received front-line hypomethylating agents. Higher blast counts (<20% vs ≥20%) were marginally associated with CK50 (p=0.08). In the OS24 analysis, blast count showed a marginal association with OS24 (HR 1.3 (95% CI 1.0 to 1.6); p=0.07), while CK50 predicted significantly inferior outcomes (HR=1.7 (95% CI 1.2 to 2.3); p=0.002). In a multivariable model including all TP53 allelic state determinants, only CK50 and complex karyotype remained relevant for predicting adverse outcomes.
199 | PEMBROLIZUMAB THERAPY INDUCES AN INFLAMMATORY RESPONSE IN LYMPHOMA PATIENTS BY RESHAPING MONOCYTES RESULTING IN HYPERPROGRESSIVE DISEASE
Tang, Xinyi , Mukherjee, Pinku , Wang, Y., Ansell, Stephen M. , Yang, Zhi-Zhang , Bhardwaj, Vaishali , Mukherjee, P., Wang, Yucai , Mondello, Patrizia , Pan‐Hammarström, Qiang

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_199 Get It

The Society of Pediatric Liver Transplantation ( SPLIT ): 2023 Registry Status
Banc‐Husu, Anna M. , Smith, Rachel , Kelly, Beau , Anand, Ravinder , Anderson, Sarah G. , Lobritto, Steven , Chapin, Catherine A. , Chartier, Marie‐Eve , Ekong, Udeme D. , Furuya, Katryn N. , García, Jennifer , González‐Peralta, Regino P. , Ibrahim, Samar H. , Kerkar, Nanda , Leung, Daniel H. , Ng, Vicky L. , Pai, Anita K., Pan, Debra H. , Shakhin, Victoria , Stoll, Janis , Wadera, Sheetal, Squires, James E. , (SPLIT), the Society of Pediatric Liver Transplantation, Lobritto, Steve , Elisofon, Scott A , Feldman, Amy , Gutierrez Sanchez, Luz Helena , Hildreth, Amber N , Himes, Ryan , Ibrahim, Samar H , Kerkar, Nanda , Leung, Daniel H , Mazareigos, George , Ng, Vicky L , Peters, Anna L , Shakhin, Victoria , Hsu, Evelyn , Squires, James E , Valentino, Pamela , Society of Pediatric Liver Transplantation (SPLIT) , Sanchez, Luz Helena Gutierrez , Hildreth, Amber , Jain, Ajay K. , Mazariegos, George , Valentino, Pamela L. , (SPLIT), the Society of Pediatric Liver Transplantation

Mayo Clinic

Pediatric Transplantation | June 16, 2025 | Volume: 29 | Issue: 5 | Pages: No page available

10.1111/petr.70111 | PMID 40522021 Get It

ABSTRACT Background The Society of Pediatric Liver Transplantation (SPLIT) has undergone tremendous growth with > 45 sites contributing data focusing on improving outcomes in pediatric liver transplantation (LT). We report and compare outcomes from the SPLIT Registry. Methods Patients < 18 years with first‐time LT only enrolled into the SPLIT Registry between 2011 and 2023 were included. Data was stratified into eras from the last published registry update (era 1: 2011–2018, era 2: 2018–2023). Results Three thousand five hundred four participants from 47 centers were included (era 1: n = 2159; era 2: n = 1345). Age distribution differed with more children < 1 year. of age at LT in era 2 (era 1: 29% vs. era 2: 33%, p = 0.01). Indications for LT were similar, with biliary atresia (38.8%) and metabolic disease (16.0%) being most common. Exception point use was higher in era 2 (era 1: 45% vs. era 2: 56%, p < 0.001). No difference in graft type (deceased: 81% era 1 vs. 78% era 2, p = 0.78), patient survival at 90 days (era 1: 98.7% vs. era 2: 98.3%), 1 year (era 1: 97.2 vs. era 2: 96.8%), or 3 years (era 1: 95.3% vs. era 2: 95.2%) was noted. Rate of hepatic artery thrombosis was lower in era 2 (era 1: 7% vs. era 2: 5%, p = 0.02). Conclusions Trends in pediatric LT within SPLIT note similar LT indications and graft type, higher utilization of exception points, and lower HAT rates despite transplanting more children < 10 kg. This data underscores the evolution of pediatric LT toward higher survivability and overall patient outcomes.
611 | TUMOR EVOLUTION AND IMMUNE MICROENVIRONMENT DYNAMICS IN PRIMARY AND RELAPSED MANTLE CELL LYMPHOMA
Wan, Hui , Ren, Weicheng , Yang, Mao , Wasik, Agata M. , Nie, M., Yang, Chuan , Ansell, Steven M., Liu, D. , Sander, Birgitta , Li, Xiangchun , Du, Lei , Campos‐Mata, Leire de , Nie, M., Ye, Xiaojing , Yang, Zhi Ping , Burg, Mirjam van der , Wu, Kui , Pan‐Hammarström, Qiang

Mayo Clinic

Hematological Oncology | June 15, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70096_611 Get It

The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms
Reis, Henning , Cunha, Isabela W. , Amin, Mahul B. , Aron, Manju , Athanazio, Daniel Abensur , Bambury, Richard , Cheng, Liang , Gopalan, Anuradha , Gulmann, Christian, Harris, Carole A. , Jiménez, Rafael E. , Jinzaki, Masahiro , Lal, Priti , Miyai, Kosuke , Netto, George J. , Pan, Chin-Chen, Rhijn, Bas W. van, Smith, Steven C. , Wobker, Sara E. , Paner, Gladell P. , Lesions, the ISUP Expert Panel on Urachal Neoplasms and Urinary Bladder Glandular, Cheng, Liang , Cheng, Liang , Al-Ahmadie, Hikmat A , Gaisa, Nadine Therese , López-Beltrán, Antonio , Maclean, Fiona M. , Tsuzuki, Toyonori , Aning, Jonathan J. , Guo, Charles Chuanhai , Iyer, Gopa , Kikuchi, Eiji , Pan, Chin‐Chen , Panebianco, Valeria , Siefker-Radtke, Arlene Odelia , Szarvas, Tibor , Kristiansen, Glen , Lesions, the ISUP Expert Panel on Urachal Neoplasms and Urinary Bladder Glandular

Mayo Clinic

American Journal of Surgical Pathology | June 5, 2025 | Volume: 49 | Issue: 11 | Pages: e18-e26

10.1097/pas.0000000000002416 | PMID 40471793 Get It

This manuscript summarizes the first part of the proceedings of the 2023 Dublin ISUP Consensus Conference encompassing the best practice recommendations on the pathology of neoplasms of urachal origin. The rationale for convening this consensus conference was the lack of structured and consented histopathologic recommendations in these rare tumors. Consensus among the meeting participants (n=80) was reached on the following statements: (1) combination of gross, histologic, clinical and imaging findings with exclusion of secondary tumor metastasis are to be used in the diagnosis of urachal carcinoma; (2) the 2022 World Health Organization (WHO) separate criteria for the diagnosis of urachal adenocarcinoma and for nonglandular carcinoma should be applied; (3) specific elements are to be evaluated and recorded in the gross examination of resection specimens containing urachal tumors; (4) sampling considerations for resection specimens containing urachal tumors are advised; (5) participants are against using 5% or 10% cutoff for the extent of intraepithelial carcinoma in urachal mucinous cystic tumor of low malignant potential; (6) use of immunohistochemical markers for the differential diagnosis of urachal adenocarcinomas in transurethral resection (TUR) specimen is considered optional; (7) similar tumor classificatory (nosology) rules for carcinomas arising from bladder mucosa (eg, urothelial carcinoma, squamous cell carcinoma, and neuroendocrine carcinoma) should be applied for nonglandular urachal carcinomas; (8) a new staging approach other than the previously proposed systems should be designed for urachal carcinoma; (9) a system modifying the current Tumor-Node-Metastasis (TNM)/American Joint Committee on Cancer (AJCC) staging system for urinary bladder cancer is considered appropriate for a study in urachal carcinoma; and (10) several histologic elements are to be reported when diagnosing urachal carcinoma in TUR and resection specimens. This report from the Dublin ISUP consensus conference will serve as a practice recommendation for pathologists and as a guide for future standardized reporting protocols and research regarding urachal tumors. In addition, an international database for urachal cancers under the guidance of ISUP is being planned to be established to address pertinent issues in the pathology of urachal cancers.